Drugs / human soluble insulin
human soluble insulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT02162407 Comparator | Oct → Dec 1999 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01486940 Comparator | Mar → Oct 2002 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01707134 Comparator | Sep 1997 → May 2000 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01486966 Comparator | Nov 2011 → Jun 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human soluble insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01486966 ↗ |
| Known as | regular human insulin | “using either the soluble long-acting basal insulin analogue, insulin detemir, in combination with the rapid-acting analogue, insulin aspart, or NPH insulin in combination with...” PMID 15298338 ↗ Apr 2004 |
| Known as | soluble human insulin | “Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes.” PMID 16054266 ↗ Jul 2005 |
| Modality | Protein / enzyme biologic | “traditional human insulins (NPH insulin and regular human insulin)” PMID 15298338 ↗ Apr 2004 |
| Route | Subcutaneous | “Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals” NCT01486940 ↗ |